The Female Health Company Remains Neutral With Respect to Partial Tender Offer
11 Abril 2007 - 10:30AM
PR Newswire (US)
CHICAGO, April 11 /PRNewswire-FirstCall/ -- The Female Health
Company (OTC:FHCO) (BULLETIN BOARD: FHCO) announced that today it
is filing a Schedule 14D-9 Solicitation/Recommendation Statement
with the Securities and Exchange Commission in response to an
unsolicited partial tender offer to purchase up to 1,200,000 shares
of the Company's common stock for $2.27 per share in cash made on
March 30, 2007 by Red Oak Fund, L.P. The Board of Directors of the
Company has determined not to make any recommendation to the
Company's shareholders as to whether they should tender their
shares in the tender offer. The Board of Directors is expressing no
opinion to the Company's shareholders and is remaining neutral with
respect to the tender offer. As stated in the Schedule 14D-9
Solicitation/Recommendation Statement that is being filed today by
the Company with the Securities and Exchange Commission, the Board
of Directors has determined that a shareholder's decision on
whether or not to tender its shares in the tender offer and, if so,
how many shares to tender, is a personal investment decision based
upon each individual stockholder's particular circumstances. The
Schedule 14D-9 Solicitation/Recommendation Statement explains in
additional detail the factors considered by the Board of Directors
in reaching its position. To the Company's knowledge, none of the
Company's executive officers or directors currently intend to
tender shares of the Company's common stock in the tender offer,
other than Stephen M. Dearholt, who has indicated that he may
tender up to 100,000 shares in the tender offer. The Board of
Directors urges each shareholder to make its own decision regarding
the tender offer based on all of the available information,
including the adequacy of the offer price in light of the
shareholder's own investment objectives, the shareholder's views as
to the Company's prospects and outlook, the factors considered by
the Board of Directors as described in the Schedule 14D-9
Solicitation/Recommendation Statement and any other factors that
the stockholder deems relevant to its investment decision. The
Board of Directors also urges each shareholder to consult with its
financial and tax advisors regarding the tender offer. The Board of
Directors urges each shareholder to read the Schedule 14D-9
Solicitation/Recommendation Statement, as well as Red Oak's Offer
to Purchase and other offer materials, prior to making any decision
regarding the tender offer. Notice to Investors This communication
is neither an offer to purchase nor a solicitation of an offer to
sell any securities. A solicitation and offer to buy shares of the
Company's common stock is being made pursuant to an offer to
purchase and related materials that Red Oak has filed with the
Securities and Exchange Commission. Red Oak has filed a tender
offer statement on Schedule TO with the Securities and Exchange
Commission and the Company is filing today a
Solicitation/Recommendation Statement on Schedule 14D-9 with
respect to the tender offer. Red Oak's Schedule TO and the
Company's Solicitation/Recommendation Statement on Schedule 14D-9
contain important information that should be read carefully and
considered before any decision is made with respect to the tender
offer. All of these materials (and all other materials filed by the
Company with the Securities and Exchange Commission) are or will be
available at no charge from the Securities and Exchange Commission
through its website at http://www.sec.gov/. Red Oak has stated that
free copies of its offer to purchase, related letter of transmittal
and certain other offering documents will be made available free of
charge by Red Oak. Investors and security holders may also obtain
free copies of the Company's Schedule 14D-9
Solicitation/Recommendation Statement and the other documents filed
with the Securities and Exchange Commission by the Company by
contacting Donna Felch, the Company's Chief Financial Officer, at
The Female Health Company, 515 North State Street, Suite 2225,
Chicago, Illinois 60610, telephone number (312) 595-9123. About The
Female Health Company, Inc. The Female Health Company, based in
Chicago, Illinois, manufactures and markets the FC Female
Condom(R), which is primarily distributed by public health
organizations and donor groups in over 90 developing countries
around the world. World-wide, the Female Condom is available in
various programs in 108 countries. The Company owns certain
worldwide rights to the FC Female Condom(R), including patents that
have been issued in the United States, United Kingdom, Japan,
France, Italy, Germany, Spain, the European Patent Convention, the
People's Republic of China, Canada, South Korea and Australia. FC
Female Condom(R) is the only available FDA-approved product
controlled by a woman that offers dual protection against sexually
transmitted diseases, including HIV/AIDS, and unintended pregnancy.
"Safe Harbor" statement under the Private Securities Litigation
Reform Action of 1995: The statements in this release which are not
historical fact are forward-looking statements based upon the
Company's current plans and strategies, and reflect the Company's
current assessment of the risks and uncertainties related to its
business, including such things as product demand and market
acceptance; the economic and business environment and the impact of
government pressures; currency risks; capacity; efficiency and
supply constraints; and other risks detailed in the Company's press
releases, shareholder communications and Securities and Exchange
Commission filings. Actual events affecting the Company and the
impact of such events on the Company's operations may vary from
those currently anticipated. For more information about the Female
Health Company visit the Company's web site at
http://www.femalehealth.com/ and http://www.femalecondom.org/ If
you would like to be added to an e-mail alert list, please send an
e-mail to Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna
Felch 312.595.9123 DATASOURCE: The Female Health Company CONTACT:
William R. Gargiulo, Jr., +1-231-526-1244, or Donna Felch,
+1-312-595-9123, both of The Female Health Company Web site:
http://www.femalehealth.com/
Copyright